MX2008016356A - Composiciones de sal de glicopirronio para inhalacion. - Google Patents

Composiciones de sal de glicopirronio para inhalacion.

Info

Publication number: MX2008016356A
Authority: MX; Mexico
Prior art keywords: process according; glycopyrronium; micronized; glycopyrronium salt; adherent agent
Prior art date: 2006-06-30

Application number

MX2008016356A

Other languages

English (en)

Spanish (es)

Inventor

Wolfgang Wirth

Anton Baumberger

Stephan Abel

Barbara Haeberlin

Frank Stowasser

Sebastian Kaerger

Thomas Kieckbusch

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-30

Filing date

2007-06-28

Publication date

2009-01-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008016356(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-28 Application filed by Novartis Ag filed Critical Novartis Ag

2009-01-16 Publication of MX2008016356A publication Critical patent/MX2008016356A/es

Links

239000000203 mixture Substances 0.000 title claims abstract description 62
ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical group C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 title claims abstract description 54
239000002245 particle Substances 0.000 claims abstract description 60
239000003795 chemical substances by application Substances 0.000 claims abstract description 52
230000000181 anti-adherent effect Effects 0.000 claims abstract description 45
239000003911 antiadherent Substances 0.000 claims abstract description 44
239000000843 powder Substances 0.000 claims abstract description 44
238000009472 formulation Methods 0.000 claims abstract description 34
238000000034 method Methods 0.000 claims abstract description 29
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 38
229960002462 glycopyrronium bromide Drugs 0.000 claims description 21
235000019359 magnesium stearate Nutrition 0.000 claims description 19
239000004480 active ingredient Substances 0.000 claims description 13
235000000346 sugar Nutrition 0.000 claims description 10
229910052751 metal Inorganic materials 0.000 claims description 9
239000002184 metal Substances 0.000 claims description 9
239000000126 substance Substances 0.000 claims description 9
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 8
238000002156 mixing Methods 0.000 claims description 8
-1 ndacaterol Chemical compound 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
239000000556 agonist Substances 0.000 claims description 7
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 6
239000003149 muscarinic antagonist Substances 0.000 claims description 6
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
229960004017 salmeterol Drugs 0.000 claims description 6
150000008163 sugars Chemical class 0.000 claims description 6
229940124630 bronchodilator Drugs 0.000 claims description 5
235000013539 calcium stearate Nutrition 0.000 claims description 5
239000008116 calcium stearate Substances 0.000 claims description 5
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 5
229960001664 mometasone Drugs 0.000 claims description 5
150000003431 steroids Chemical class 0.000 claims description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 3
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
230000001387 anti-histamine Effects 0.000 claims description 3
230000003110 anti-inflammatory effect Effects 0.000 claims description 3
239000000739 antihistaminic agent Substances 0.000 claims description 3
239000003434 antitussive agent Substances 0.000 claims description 3
229940124584 antitussives Drugs 0.000 claims description 3
239000000850 decongestant Substances 0.000 claims description 3
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 3
ANGKOCUUWGHLCE-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester Chemical group C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-UHFFFAOYSA-N 0.000 claims 2
108090000312 Calcium Channels Proteins 0.000 claims 1
102000003922 Calcium Channels Human genes 0.000 claims 1
239000002876 beta blocker Substances 0.000 claims 1
229940097320 beta blocking agent Drugs 0.000 claims 1
102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 claims 1
108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract description 3
VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 22
239000010419 fine particle Substances 0.000 description 21
239000008186 active pharmaceutical agent Substances 0.000 description 20
229940088679 drug related substance Drugs 0.000 description 19
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 13
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
238000003860 storage Methods 0.000 description 10
229940015042 glycopyrrolate Drugs 0.000 description 9
229960001375 lactose Drugs 0.000 description 9
239000008101 lactose Substances 0.000 description 9
239000000463 material Substances 0.000 description 8
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 7
229960001021 lactose monohydrate Drugs 0.000 description 7
239000002775 capsule Substances 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
229960004977 anhydrous lactose Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000000227 grinding Methods 0.000 description 5
229960004078 indacaterol Drugs 0.000 description 5
QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 5
239000013543 active substance Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000012530 fluid Substances 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 description 3
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 3
229960003728 ciclesonide Drugs 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000009826 distribution Methods 0.000 description 3
229940112141 dry powder inhaler Drugs 0.000 description 3
238000013101 initial test Methods 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 2
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
150000002016 disaccharides Chemical class 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000008103 glucose Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000003801 milling Methods 0.000 description 2
150000002772 monosaccharides Chemical class 0.000 description 2
OKFDRAHPFKMAJH-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide Chemical compound C=12C3=CC(NS(=O)(=O)C)=CC=C3OC2=C(OC(F)F)C=CC=1C(=O)NC1=C(Cl)C=NC=C1Cl OKFDRAHPFKMAJH-UHFFFAOYSA-N 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000005846 sugar alcohols Chemical class 0.000 description 2
238000012360 testing method Methods 0.000 description 2
HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 1
SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
DCYGAPKNVCQNOE-UHFFFAOYSA-N 2,2,2-triphenylacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1 DCYGAPKNVCQNOE-UHFFFAOYSA-N 0.000 description 1
PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 description 1
KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
IFLKEBSJTZGCJG-UHFFFAOYSA-N 3-methylthiophene-2-carboxylic acid Chemical compound CC=1C=CSC=1C(O)=O IFLKEBSJTZGCJG-UHFFFAOYSA-N 0.000 description 1
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000132092 Aster Species 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
101150015280 Cel gene Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241001440269 Cutina Species 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
101150099798 GSK1 gene Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
RUOGJYKOQBFJIG-UHFFFAOYSA-N SCH-351591 Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)NC1=C(Cl)C=[N+]([O-])C=C1Cl RUOGJYKOQBFJIG-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
YJBKAMMKXVRSAI-CUCKRJOPSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-fluorophenyl)-n-[(3,4,5-trifluorophenyl)methyl]carbamate;(2s,3s)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.FC1=CC=CC(N(CC=2C=C(F)C(F)=C(F)C=2)C(=O)O[C@@H]2C3CCN(CC3)C2)=C1 YJBKAMMKXVRSAI-CUCKRJOPSA-N 0.000 description 1
YPFLFUJKZDAXRA-UHFFFAOYSA-N [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate Chemical compound O1C2=CC(OS(=O)(=O)C)=CC=C2C(NC(N)=O)=C1C(=O)C1=CC=C(Cl)C=C1Cl YPFLFUJKZDAXRA-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229960000528 amlodipine Drugs 0.000 description 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000001022 anti-muscarinic effect Effects 0.000 description 1
239000000596 artificial lung surfactant Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
210000003123 bronchiole Anatomy 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
229940078456 calcium stearate Drugs 0.000 description 1
229950010713 carmoterol Drugs 0.000 description 1
238000007705 chemical test Methods 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
229950001653 cilomilast Drugs 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
239000011246 composite particle Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
229960003580 felodipine Drugs 0.000 description 1
229960001022 fenoterol Drugs 0.000 description 1
229960002714 fluticasone Drugs 0.000 description 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
239000011888 foil Substances 0.000 description 1
229960002848 formoterol Drugs 0.000 description 1
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229960001361 ipratropium bromide Drugs 0.000 description 1
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
229960004427 isradipine Drugs 0.000 description 1
229960004340 lacidipine Drugs 0.000 description 1
GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
229960004294 lercanidipine Drugs 0.000 description 1
ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
229960001783 nicardipine Drugs 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960000715 nimodipine Drugs 0.000 description 1
229960000227 nisoldipine Drugs 0.000 description 1
229950000175 oglemilast Drugs 0.000 description 1
229960002657 orciprenaline Drugs 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
229960001609 oxitropium bromide Drugs 0.000 description 1
LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229960002288 procaterol Drugs 0.000 description 1
FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
238000011084 recovery Methods 0.000 description 1
MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
229960002586 roflumilast Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000005204 segregation Methods 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Otolaryngology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MX2008016356A 2006-06-30 2007-06-28 Composiciones de sal de glicopirronio para inhalacion. MX2008016356A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0613161.9A GB0613161D0 (en)	2006-06-30	2006-06-30	Organic Compounds
PCT/EP2007/005744 WO2008000482A1 (fr)	2006-06-30	2007-06-28	Compositions à inhaler à base d'un sel de glycopyrronium

Publications (1)

Publication Number	Publication Date
MX2008016356A true MX2008016356A (es)	2009-01-16

Family

ID=36888514

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2008016356A MX2008016356A (es)	2006-06-30	2007-06-28	Composiciones de sal de glicopirronio para inhalacion.

Country Status (16)

Country	Link
US (4)	US20090209502A1 (fr)
EP (1)	EP2037879B1 (fr)
JP (1)	JP5266213B2 (fr)
KR (1)	KR101400579B1 (fr)
CN (1)	CN101484134B (fr)
AU (1)	AU2007264000B2 (fr)
BR (1)	BRPI0713777B8 (fr)
CA (1)	CA2655381C (fr)
ES (1)	ES2424754T3 (fr)
FR (1)	FR13C0059I1 (fr)
GB (1)	GB0613161D0 (fr)
MX (1)	MX2008016356A (fr)
PL (1)	PL2037879T3 (fr)
PT (1)	PT2037879E (fr)
RU (1)	RU2453302C2 (fr)
WO (1)	WO2008000482A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
SI1494732T1 (sl)	2002-03-20	2008-08-31	Mannking Corp	Inhalacijski aparat
KR101273120B1 (ko)	2004-08-20	2013-06-13	맨카인드 코포레이션	다이케토피페라진 합성의 촉매 작용
BR122019022692B1 (pt)	2004-08-23	2023-01-10	Mannkind Corporation	Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
KR101486829B1 (ko)	2005-09-14	2015-01-29	맨카인드 코포레이션	결정질 미립자 표면에 대한 활성제의 친화력의 증가를 기반으로 하는 약물 제제의 방법
EP1986679B1 (fr)	2006-02-22	2017-10-25	MannKind Corporation	Procédé pour améliorer les propriétés pharmaceutiques de microparticules comprenant de la dicétopipérazine et un agent actif
EP2234595B1 (fr) *	2007-12-13	2012-11-28	Novartis AG	Procédé pour réduire la tendance d'un sel glycopyrronium pour agréger pendant le stockage.
TWI677355B (zh)	2008-06-13	2019-11-21	美商曼凱公司	用於藥物傳輸之乾粉吸入器及系統
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2421385T3 (es)	2008-06-20	2013-09-02	Mannkind Corp	Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (fr)	2009-03-11	2017-03-01	MannKind Corporation	Appareil, système et procédé de mesure de résistance d'un inhalateur
US20120022127A1 (en)	2009-04-09	2012-01-26	Thomas Allmendinger	Process for preparing pyrrolidinium salts
US8815258B2 (en)	2009-05-29	2014-08-26	Pearl Therapeutics, Inc.	Compositions, methods and systems for respiratory delivery of two or more active agents
EP3106149B1 (fr) *	2009-05-29	2019-11-20	Pearl Therapeutics, Inc.	Compositions pour l'administration par voie pulmonaire d'antagonistes muscariniques et agonistes du récepteur adrénergique béta-2 à action prolongée, procédés et systèmes associés
MY186975A (en)	2009-06-12	2021-08-26	Mannkind Corp	Diketopiperazine microparticles with defined specific surface areas
US9016147B2 (en)	2009-11-03	2015-04-28	Mannkind Corporation	Apparatus and method for simulating inhalation efforts
GB0921481D0 (en)	2009-12-08	2010-01-20	Vectura Ltd	Process and product
RS53391B2 (sr) *	2009-12-23	2023-09-29	Chiesi Farm Spa	Kombinovana terapija copd-a (hroničnih obstruktivnih bolesti pluća)
WO2011076842A2 (fr)	2009-12-23	2011-06-30	Chiesi Farmaceutici S.P.A.	Préparation aérosol pour copd (bronchopneumopathie chronique obstructive)
CA2785349C (fr) *	2009-12-23	2018-07-03	Chiesi Farmaceutici S.P.A.	Polytherapie destinee a la bronchopneumopathie chronique obstructive
BR112012015335B1 (pt) *	2009-12-23	2021-05-18	Chiesi Farmaceutici S.P.A.	formulação de aerossol para doença pulmonar obstrutiva crõnica
KR101736529B1 (ko)	2010-06-14	2017-05-17	키에시 파르마슈티시 엣스. 피. 에이.	글리코피로늄 클로라이드의 결정형
BR112012029824A2 (pt) *	2010-06-14	2016-08-09	Chiesi Farma Spa	métodos para o preparo de cloreto de glicopirrônio, cloreto de glicopirrônio, composição farmacêutica e uso de cloreto de glicopirrônio
MX359281B (es)	2010-06-21	2018-09-21	Mannkind Corp	Sistema y metodos para suministrar un farmaco en polvo seco.
CA2807256C (fr) *	2010-08-03	2018-08-28	Chiesi Farmaceutici S.P.A.	Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
PL2621494T3 (pl) *	2010-09-30	2019-04-30	Chiesi Farm Spa	Zastosowanie stearynianu magnezu w preparatach w postaci suchego proszku do inhalacji
JO3510B1 (ar) *	2011-03-04	2020-07-05	Heptares Therapeutics Ltd	استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
US8925726B2 (en)	2011-04-01	2015-01-06	Mannkind Corporation	Blister package for pharmaceutical cartridges
WO2012174472A1 (fr)	2011-06-17	2012-12-20	Mannkind Corporation	Microparticules de dicétopipérazine de capacité élevée
ES2761316T3 (es)	2011-07-13	2020-05-19	Pharmaxis Ltd	Mejoras relacionadas con dispositivos de suministro
EP2731571B1 (fr)	2011-07-13	2019-12-18	Pharmaxis Ltd	Perfectionnements relatifs à des dispositifs d'administration
US10786637B2 (en)	2011-07-13	2020-09-29	Pharmaxis Ltd.	Delivery devices
CA2852536A1 (fr)	2011-10-24	2013-05-02	Mannkind Corporation	Procedes et compositions pour traiter la douleur
US20150202148A1 (en) *	2012-07-05	2015-07-23	Arven llac Sanayi Ve Ticaret Anonim Sirketi	Dry powder inhalers comprising a carrier other than lactose
WO2014007771A2 (fr)	2012-07-05	2014-01-09	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Compositions d'inhalation comprenant un antagoniste du récepteur muscarinique
US10111957B2 (en)	2012-07-05	2018-10-30	Arven Ilac Snayi ve Ticaret A.S.	Inhalation compositions comprising glucose anhydrous
US20150202297A1 (en) *	2012-07-05	2015-07-23	Arven Ilac Sanayi Ve Ticaret Anonim Sirketi	Dry powder inhalers comprising a carrier other than lactose and a ternary component
CA2878457C (fr)	2012-07-12	2021-01-19	Mannkind Corporation	Systemes et procedes de liberation de medicament en poudre seche
EP2911690A1 (fr)	2012-10-26	2015-09-02	MannKind Corporation	Compositions et procédés de vaccin antigrippal inhalable
AU2013100007B4 (en) *	2013-01-04	2013-05-23	Novartis Ag	System for treating chronic obstructive pulmonary disease
US9452139B2 (en)	2013-03-14	2016-09-27	Novartis Ag	Respirable agglomerates of porous carrier particles and micronized drug
EP2970149B1 (fr)	2013-03-15	2019-08-21	MannKind Corporation	Compositions de dicétopipérazine microcristallines et procédés
BR112015022784B1 (pt)	2013-03-15	2023-02-14	Pearl Therapeutics, Inc	Método de condicionamento de material cristalino micronizado e sistemas de condicionamento
GB201305825D0 (en)	2013-03-28	2013-05-15	Vectura Ltd	New use
US9393202B2 (en) *	2013-04-26	2016-07-19	Chiesi Farmaceutici S.P.A	Particle size reduction of an antimuscarinic compound
MY176176A (en)	2013-07-11	2020-07-24	Chiesi Farm Spa	Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
EP3021834A1 (fr)	2013-07-18	2016-05-25	MannKind Corporation	Compositions pharmaceutiques en poudre sèche stables à la chaleur et procédés
CN105517607A (zh)	2013-08-05	2016-04-20	曼金德公司	吹入设备和方法
CN105848642A (zh)	2013-12-30	2016-08-10	奇斯药制品公司	格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
GB201415381D0 (en) *	2014-08-29	2014-10-15	Algipharma As	Inhalable powder formulations of alginate oligomers
BR112017003888B1 (pt) *	2014-09-09	2022-11-16	Vectura Limited	Método de fabricação de uma formulação de pó seco
CN105412049B (zh) *	2014-09-16	2020-01-07	四川海思科制药有限公司	一种干粉吸入剂用药物组合物及其制备方法
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
WO2016071862A1 (fr) *	2014-11-05	2016-05-12	Glenmark Pharmaceuticals Limited	Composition pharmaceutique inhalable comportant du glycopyrronium
GB201515310D0 (en) *	2015-08-27	2015-10-14	Jagotec Ag	Pharmaceutical composition
US9925168B2 (en) *	2016-01-22	2018-03-27	Chiesi Farmaceutici S.P.A.	Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
TWI745396B (zh)	2016-07-12	2021-11-11	日商鹽野義製藥股份有限公司	吸入用醫藥組成物
WO2018167180A1 (fr) *	2017-03-15	2018-09-20	Vectura Limited	Procédé et formulation
CN119656140A (zh) *	2017-05-11	2025-03-21	奇斯药制品公司	制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
RU2742376C1 (ru) *	2017-05-11	2021-02-05	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик
CN107213141A (zh) *	2017-06-09	2017-09-29	中国药科大学	用于吸入的药物组合物
CN109200034A (zh) *	2017-06-30	2019-01-15	正大天晴药业集团股份有限公司	一种可吸入干粉形式的组合物及其制备方法
CN116173025A (zh) *	2018-07-26	2023-05-30	四川海思科制药有限公司	一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
WO2020019953A1 (fr) *	2018-07-26	2020-01-30	四川海思科制药有限公司	Composition pharmaceutique aérosol renfermant un glycopyrrolate, son procédé de préparation et ses applications
KR102696616B1 (ko)	2018-12-21	2024-08-20	한미약품 주식회사	흡입 제형용 건조 분말 및 이의 제조방법
CN109745565B (zh) *	2019-01-28	2021-05-18	上海方予健康医药科技有限公司	一种用于吸入的干粉组合物及其制备方法
EP4034079A1 (fr) *	2019-09-24	2022-08-03	Chiesi Farmaceutici S.p.A.	Nouvelles particules de support pour formulations de poudre sèche pour inhalation
CN116194087B (zh) *	2020-01-15	2025-07-11	四川海思科制药有限公司	一种含茚达特罗的吸入气雾剂药物组合物及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2956062A (en)	1959-02-26	1960-10-11	Robins Co Inc A H	Esters of amino alcohols
GB9501841D0 (en) *	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
US6613795B2 (en)	1996-11-11	2003-09-02	Christian Noe	Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
EP1369414A1 (fr)	1996-11-11	2003-12-10	Christian R. Noe	Arylcycloalkyls hydroxyesters énantiomériquement purs, procédé pour leur préparation et leur utilisation comme modulateurs de récepteurs muscariniques
RU2221552C2 (ru)	1998-11-13	2004-01-20	Джаго Рисерч Аг	Сухой порошок для ингаляции
GB9826783D0 (en)	1998-12-04	1999-01-27	Scherer Ltd R P	Inhalation powders
JP2001151673A (ja) *	1999-09-06	2001-06-05	Nikken Chem Co Ltd	吸入用粉末製剤の製造方法
GB0008660D0 (en) *	2000-04-07	2000-05-31	Arakis Ltd	The treatment of respiratory diseases
PE20011227A1 (es) *	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
EP2266549B1 (fr)	2000-06-27	2019-08-07	Vectura Limited	Procedé permettant de produire des particules destinées à être utilisées dans une composition pharmaceutique
DK2283818T3 (en)	2000-11-30	2017-10-16	Vectura Ltd	Process for preparing particles for use in a pharmaceutical composition
US6634466B1 (en) *	2001-12-12	2003-10-21	Master Concepts, Inc.	Brake pedal fastener
JP2006522634A (ja)	2003-04-14	2006-10-05	ベクトゥラ・リミテッド	投与効率を向上させるデバイス及び製薬組成
US20060292081A1 (en)	2003-09-15	2006-12-28	Vectura Limited	Methods for preparing pharmaceutical compositions
WO2005025550A1 (fr)	2003-09-15	2005-03-24	Vectura Limited	Compositions pharmaceutiques permettant de traiter l'ejaculation precoce par inhalation pulmonaire
GB0327723D0 (en)	2003-09-15	2003-12-31	Vectura Ltd	Pharmaceutical compositions
GB0321607D0 (en)	2003-09-15	2003-10-15	Vectura Ltd	Manufacture of pharmaceutical compositions
GB0324918D0 (en)	2003-10-24	2003-11-26	Glaxo Group Ltd	Composition
GB0326632D0 (en)	2003-11-14	2003-12-17	Jagotec Ag	Dry powder formulations
GB0409703D0 (en)	2004-04-30	2004-06-02	Vectura Ltd	Pharmaceutical compositions
GB0410399D0 (en)	2004-05-10	2004-06-16	Arakis Ltd	The treatment of respiratory disease
GB0525254D0 (en)	2005-12-12	2006-01-18	Jagotec Ag	Powder compositions for inhalation

2006
- 2006-06-30 GB GBGB0613161.9A patent/GB0613161D0/en not_active Ceased
2007
- 2007-06-28 CA CA2655381A patent/CA2655381C/fr active Active
- 2007-06-28 RU RU2009102934/15A patent/RU2453302C2/ru active
- 2007-06-28 PL PL07764925T patent/PL2037879T3/pl unknown
- 2007-06-28 CN CN2007800250151A patent/CN101484134B/zh active Active
- 2007-06-28 AU AU2007264000A patent/AU2007264000B2/en active Active
- 2007-06-28 WO PCT/EP2007/005744 patent/WO2008000482A1/fr not_active Ceased
- 2007-06-28 JP JP2009516996A patent/JP5266213B2/ja active Active
- 2007-06-28 EP EP07764925.9A patent/EP2037879B1/fr not_active Revoked
- 2007-06-28 ES ES07764925T patent/ES2424754T3/es active Active
- 2007-06-28 BR BRPI0713777A patent/BRPI0713777B8/pt active IP Right Grant
- 2007-06-28 KR KR1020087031818A patent/KR101400579B1/ko active Active
- 2007-06-28 US US12/305,263 patent/US20090209502A1/en not_active Abandoned
- 2007-06-28 MX MX2008016356A patent/MX2008016356A/es active IP Right Grant
- 2007-06-28 PT PT77649259T patent/PT2037879E/pt unknown
2011
- 2011-10-12 US US13/271,689 patent/US20120065174A1/en not_active Abandoned
2013
- 2013-11-08 FR FR13C0059C patent/FR13C0059I1/fr active Active
2015
- 2015-04-21 US US14/692,033 patent/US20150224194A1/en not_active Abandoned
- 2015-12-07 US US14/960,472 patent/US10314784B2/en active Active

Also Published As

Publication number	Publication date
US20150224194A1 (en)	2015-08-13
CA2655381C (fr)	2014-10-21
AU2007264000A1 (en)	2008-01-03
US20160081934A1 (en)	2016-03-24
FR13C0059I1 (fr)	2013-12-13
KR101400579B1 (ko)	2014-05-28
US20120065174A1 (en)	2012-03-15
US10314784B2 (en)	2019-06-11
CN101484134A (zh)	2009-07-15
BRPI0713777B8 (pt)	2021-05-25
PL2037879T3 (pl)	2013-09-30
JP2009541393A (ja)	2009-11-26
ES2424754T3 (es)	2013-10-08
RU2453302C2 (ru)	2012-06-20
CN101484134B (zh)	2012-08-08
CA2655381A1 (fr)	2008-01-03
WO2008000482A1 (fr)	2008-01-03
KR20090023650A (ko)	2009-03-05
EP2037879A1 (fr)	2009-03-25
EP2037879B1 (fr)	2013-05-15
GB0613161D0 (en)	2006-08-09
RU2009102934A (ru)	2010-08-10
AU2007264000B2 (en)	2011-06-09
BRPI0713777B1 (pt)	2019-08-27
US20090209502A1 (en)	2009-08-20
PT2037879E (pt)	2013-08-27
JP5266213B2 (ja)	2013-08-21
BRPI0713777A2 (pt)	2012-10-30

Publication	Publication Date	Title
US10314784B2 (en)	2019-06-11	Compositions of glycopyrronium salt for inhalation
EP2104490B1 (fr)	2019-07-03	Particules micronisées d'agents actifs à faible puissance posologique pour des formulations en poudre pour inhalation
US10966991B2 (en)	2021-04-06	Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
US20200155506A1 (en)	2020-05-21	Formulation comprising glycopyrrolate, method and apparatus
CN107213141A (zh)	2017-09-29	用于吸入的药物组合物
GB2434098A (en)	2007-07-18	Process for the preparation of an inhalable dry powder formulation
HK40035236A (en)	2021-05-14	Formulation comprising glycopyrrolate, method and apparatus
HK1241279A1 (en)	2018-06-08	Formulation comprising glycopyrrolate, method and apparatus
HK1241279B (en)	2021-01-08	Formulation comprising glycopyrrolate, method and apparatus
WO2019060595A1 (fr)	2019-03-28	Médicament inhalable en poudre sèche comprenant du glycopyrronium

Legal Events

Date	Code	Title	Description
2010-08-31	HH	Correction or change in general
2013-05-22	FG	Grant or registration